US · Healthcare · Biotechnology
EPS came in at -0.90 against a street estimate of -0.70 — a miss of 28.6%.
Analysts rate CG Oncology, Inc. Common stock a buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $91.08.
| Fund | Stake |
|---|---|
| RTW INVESTMENTS, LLC | 7.88% |
| T. Rowe Price Investment Management,Inc. | 7.58% |
| Decheng Capital LLC | 7.19% |
| Wellington Management Company LLP | 6.01% |
| BlackRock Inc | 5.71% |
| FMR Inc | 4.25% |
| TCG Crossover Management, LLC | 4.14% |
| T. Rowe Price Associates, Inc. | 4.12% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CG ONCOLOGY, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS Q2 2026 (Six Months Ended June 30, 2026) --- HEADLINE NUMBERS • Cash & Investments: $1,028.3 | 2026-08-06 |
| Results announced · Q3 2026 CG ONCOLOGY Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $1.0 billion in cash, cash equivalents and marketable securities as | 2026-08-06 |
| Shareholder vote results · Q2 2026 CG ONCOLOGY, INC. - 8-K SUMMARY (June 4, 2026 Annual Meeting) HEADLINE NUMBERS • Outstanding shares as of April 7, 2026 (record date): 88,009,980 sh | 2026-06-08 |
| Board / officer change · Q2 2026 CG ONCOLOGY, INC. (CGON) — 8-K SUMMARY HEADLINE NUMBERS • Company: CG Oncology, Inc., oncology-focused biotech firm listed on Nasdaq (ticker: CGON) | 2026-05-26 |
| Quarterly report · Q1 2026 CG ONCOLOGY, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $1,076.2 million as of March 31, 2026 (up from $742.2 mill | 2026-05-08 |
| Results announced · Q2 2026 CG ONCOLOGY Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $1.1 billion in cash, cash equivalents and marketable securities as | 2026-05-08 |
| Proxy statement · Q2 2026 PROXY SUMMARY: CG ONCOLOGY, INC. – 2026 ANNUAL MEETING --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 2 Class II director nominees to serv | 2026-04-24 |
| Annual report FY2025 CG ONCOLOGY, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: CG Oncology, Inc. (NASDAQ: CGON) — late-stage clinical biopharmace | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| BLA completion expected Q4 2026; Phase 3 data anticipated H1 2026 CG Oncology, a biotech company developing bladder cancer treatments, reported Q1 2026 results with significant progress on its lead drug cretostimogene. Key highlights: The company expects t | 2026-05-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CG Oncology, Inc. Common stock — free to start.
Google PlayApp StoreData updated 2026-09-18.